Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Jan;22(1):27-33.
doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11.

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

Bálint Tobiás  1 , Csaba Halászlaki  2 , Bernadett Balla  2 , János P Kósa  2   3 , Kristóf Árvai  3 , Péter Horváth  2 , István Takács  2 , Zsolt Nagy  2 , Evelin Horváth  2 , János Horányi  4 , Balázs Járay  5 , Eszter Székely  5 , Tamás Székely  5 , Gabriella Győri  6 , Zsuzsanna Putz  2 , Magdolna Dank  2 , Zsuzsanna Valkusz  7 , Béla Vasas  8 , Béla Iványi  8 , Péter Lakatos  2
Affiliations
Free article
Comparative Study

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

Bálint Tobiás et al. Pathol Oncol Res. 2016 Jan.
Free article

Abstract

The incidence of thyroid cancers is increasing worldwide. Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer. In our study, we analyzed these genetic alterations in 394 thyroid tissue samples (197 papillary carcinomas and 197 healthy). The somatic mutations and translocations were detected by Light Cycler melting method and Real-Time Polymerase Chain Reaction techniques, respectively. In tumorous samples, 86 BRAF (44.2%), 5 NRAS (3.1%), 2 HRAS (1.0%) and 1 KRAS (0.5%) mutations were found, as well as 9 RET/PTC1 (4.6%) and 1 RET/PTC3 (0.5%) translocations. No genetic alteration was seen in the non tumorous control thyroid tissues. No correlation was detected between the genetic variants and the pathological subtypes of papillary cancer as well as the severity of the disease. Our results are only partly concordant with the data found in the literature.

Keywords: BRAF; Mutation; Papillary thyroid cancer; RAS; RET/PTC.

PubMed Disclaimer

References

    1. Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 - PubMed
    1. Endocr Rev. 2007 Dec;28(7):742-62 - PubMed
    1. Thyroid. 2002 Oct;12(10):903-7 - PubMed
    1. Endocr Pathol. 2002 Spring;13(1):3-16 - PubMed
    1. Thyroid. 2014 Aug;24(8):1256-66 - PubMed

Publication types

MeSH terms